Preventing graft-versus-host disease in children after stem cell transplant
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a combination of three drugs (cyclophosphamide, sirolimus, and VIC-1911) to prevent graft-versus-host disease (GVHD), a common complication after a stem cell transplant. It is for children aged 8-18 with certain blood diseases who are undergoing a haploidentical stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 8 and 18 years old.
- You must have a blood disease like acute myeloid leukemia, high-risk acute lymphoblastic leukemia, or myelodysplastic syndrome that is in remission or has certain high-risk features.
- You must have a donor who is half-matched (haploidentical) for stem cell transplant.
- You must be in generally good health (Karnofsky score of 80 or higher) and have adequate organ function (kidney, liver, lungs, and heart).
- You must not have severe other medical conditions, uncontrolled infections, or certain heart or eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
Hear when a new GVHD (Acute or Chronic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.